Table 3.
Laboratory results of the entire cohort at a patient’s first clinic visit
| Risk factor |
With CVD |
Without CVD |
P-value |
|---|---|---|---|
| N = 111 | N = 298 | ||
| Total cholesterol (mmol/L) |
7.8(2.1) |
8.7(2.0) |
<0.001 |
| Mean (SD) | |||
| HDL cholesterol (mmol/L) |
1.2(0.4) |
1.3(0.4) |
0.001 |
| Mean (SD) | |||
| LDL-cholesterol (mmol/L) |
5.7(2.0) |
6.6(1.9) |
<0.001 |
| Mean (SD) | |||
| Triglycerides (mmol/L) |
1.6(0.9) |
1.7(1.2) |
0.509 |
| Mean (SD) | |||
| TC/HDL |
7.1(3.5) |
7.0(2.7) |
0.724 |
| Mean (SD) |
|
|
|
| Lp (a) (mg/L)* |
349.0 |
262.6 |
0.166 |
| Median (IQR) |
(122.0,841.2) |
(104.4,605.1) |
|
| Fasting blood sugar (mmol/L) |
5.4(0.6) |
5.1(0.5) |
0.001 |
| Mean (SD) | |||
| Lipid lowering therapy (%) | 33.3 | 25.8 | 0.139 |
*:Lp (a) analysis carried out on the 84 FH patients with CVD and Lp (a) data available and the 200 FH patients with no CVD and Lp (a) data available.